CHI3L1 monoclonal antibody therapy mitigates cognitive impairment by inhibiting neuroinflammation through ERK and NF-κB pathway in Tg2576 mice.
Saved in:
| Title: | CHI3L1 monoclonal antibody therapy mitigates cognitive impairment by inhibiting neuroinflammation through ERK and NF-κB pathway in Tg2576 mice. |
|---|---|
| Authors: | Ham HJ; College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, North Chungcheong, Republic of Korea., Park SS; College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, North Chungcheong, Republic of Korea., Lee YS; College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, North Chungcheong, Republic of Korea., Kim TH; College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, North Chungcheong, Republic of Korea., Son DJ; College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, North Chungcheong, Republic of Korea., Kim JH; College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, North Chungcheong, Republic of Korea., Lim KH; College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, North Chungcheong, Republic of Korea., Park H; College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, North Chungcheong, Republic of Korea., Lee HJ; College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, North Chungcheong, Republic of Korea., Yun J; College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, North Chungcheong, Republic of Korea., Han SB; College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, North Chungcheong, Republic of Korea., Choi MK; College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, North Chungcheong, Republic of Korea., Hong JT; College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, North Chungcheong, Republic of Korea. |
| Source: | Frontiers in molecular neuroscience [Front Mol Neurosci] 2026 Jan 07; Vol. 18, pp. 1728279. Date of Electronic Publication: 2026 Jan 07 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101477914 Publication Model: eCollection Cited Medium: Print ISSN: 1662-5099 (Print) Linking ISSN: 16625099 NLM ISO Abbreviation: Front Mol Neurosci Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
